Journal: Breast Cancer Research : BCR
Article Title: Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
doi: 10.1186/s13058-020-01280-z
Figure Lengend Snippet: Analysis of HER family members and associated signaling pathways in representative vehicle- and Pan-HER-treated TNBC PDXs. a Representative PDX tumor models BCM-2665, BCM-3107 (subgroup 2), BCM-4913, and BMC-3555 (subgroup 1) treated with either vehicle control or Pan-HER for 3 cycles were collected at the end of the experiment (day 21 following the initial injection) and analyzed by Western blot ( a ) or immunohistochemistry ( b ). Western blot analysis of tumor lysates was used to determine HER family members EGFR and HER3, as well as associated signaling pathways including pEGFR, pHER3, FAK, AKT, and ERK pathways. A representative image is shown. β-actin levels were used as loading controls. Each Western blot lane corresponds to an individual PDX/mouse of the designated group. b Representative immunohistochemistry analysis of human EGFR and HER3 protein expression was performed in preparations of TNBC tumor samples as described in “ ”; samples were collected as described above. Counterstain: hematoxylin; here where it says "magnification x 4", it should say "magnification x 20".
Article Snippet: Pan-HER, a mixture of six monoclonal antibodies directed against each of the HER family members EGFR, HER2, and HER3, was generously provided by Symphogen A/S (Denmark) [ , , ].
Techniques: Injection, Western Blot, Immunohistochemistry, Expressing
